Replies to post #104629 on Biotech Values

[zipjet]

the way I see it other companies will have to do biosimilars (run trials to get their products approved) whereas they can probably get away with biogeneric because they may not need trials.

that would be a huge differenciation.

Thanks that is fascinating.

It also makes sense. IF a company can completely characterize and accurately control manufacturing, then trials are not necessary. Admittedly, that is a BIG IF. But if any company can do this, MNTA is it. Yes, I'm long. :-)

ij

[DewDiligence]

See #msg-26837144 (eom).